Bruker (NASDAQ:BRKR) Trading Down 5.8% After Insider Selling

Bruker Corporation (NASDAQ:BRKR)’s share price dropped 5.8% on Tuesday after an insider sold shares in the company. The company traded as low as $50.05 and last traded at $50.31. Approximately 548,473 shares changed hands during trading, a decline of 76% from the average daily volume of 2,271,825 shares. The stock had previously closed at $53.41.

Specifically, VP Mark Munch sold 7,000 shares of the business’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $55.00, for a total transaction of $385,000.00. Following the completion of the sale, the vice president directly owned 128,443 shares in the company, valued at $7,064,365. The trade was a 5.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Analyst Ratings Changes

BRKR has been the subject of several analyst reports. TD Cowen increased their target price on shares of Bruker from $42.00 to $53.00 and gave the stock a “hold” rating in a report on Wednesday, January 7th. Cowen reissued a “hold” rating on shares of Bruker in a research note on Wednesday, January 7th. Rothschild & Co Redburn began coverage on shares of Bruker in a research note on Thursday, November 20th. They set a “buy” rating and a $60.00 target price on the stock. Guggenheim upped their target price on shares of Bruker from $45.00 to $53.00 and gave the stock a “buy” rating in a report on Monday, January 5th. Finally, JPMorgan Chase & Co. upped their price objective on Bruker from $50.00 to $55.00 and gave the stock an “overweight” rating in a research note on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Bruker currently has an average rating of “Hold” and a consensus target price of $52.29.

Bruker Stock Performance

The firm has a market capitalization of $7.51 billion, a PE ratio of -309.03, a P/E/G ratio of 6.34 and a beta of 1.17. The business has a 50-day simple moving average of $47.02 and a 200-day simple moving average of $40.01. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.85 and a quick ratio of 0.91.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Monday, November 3rd. The medical research company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.33 by $0.12. Bruker had a negative net margin of 0.61% and a positive return on equity of 15.45%. The company had revenue of $860.50 million for the quarter, compared to the consensus estimate of $847.40 million. During the same quarter last year, the firm posted $0.60 EPS. The firm’s revenue was down .5% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. Equities research analysts expect that Bruker Corporation will post 2.69 earnings per share for the current fiscal year.

Bruker Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 2nd. Shareholders of record on Monday, December 8th were paid a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.4%. The ex-dividend date was Monday, December 8th. Bruker’s payout ratio is presently -125.00%.

Institutional Investors Weigh In On Bruker

Hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada boosted its holdings in Bruker by 8.3% in the 1st quarter. Royal Bank of Canada now owns 123,336 shares of the medical research company’s stock worth $5,148,000 after buying an additional 9,501 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Bruker in the 1st quarter valued at approximately $262,000. Goldman Sachs Group Inc. grew its holdings in shares of Bruker by 107.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,465,319 shares of the medical research company’s stock worth $61,162,000 after purchasing an additional 758,301 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Bruker by 2.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 366,204 shares of the medical research company’s stock valued at $15,285,000 after acquiring an additional 9,235 shares during the last quarter. Finally, Focus Partners Wealth lifted its stake in Bruker by 115.0% during the first quarter. Focus Partners Wealth now owns 11,232 shares of the medical research company’s stock worth $469,000 after purchasing an additional 6,008 shares in the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.